in overall prevalence. This rapid rise in overweight and obesity and its well known consequences of increased relative risk for various chronic conditions, including type II diabetes, cardiovascular disease and several forms of cancer, demand that researchers and policymakers consider novel approaches to improving our understanding of the measures, causes, prevention, treatment and consequences of obesity. We must also focus our attention on the effective transfer of our knowledge into improved health and a more effective health care system.
In June 2000, Canada created a new national health research funding agency called the Canadian Institutes of Health Research (CIHR). The CIHR is composed of 13 virtual institutes of health including the Institute of Nutrition, Metabolism and Diabetes. The INMD has a broad mandate to support research to enhance health in relation to diet, digestion, excretion and metabolism; and to address causes, prevention, screening, diagnosis, treatment, support systems and palliation for a wide range of conditions and problems associated with hormone, digestive system, kidney and liver function. Unique among national health research funding bodies, CIHR's mandate is to support basic biomedical and clinical research, as well as research into health services and systems, the health of populations, social and cultural dimensions of health and environmental influences on health.
As a result of the creation of CIHR and its 13 institutes of health, Canada has for the first time in its history a health research funding agency structured to allow for the identification of strategic priorities and for the targeting of health research dollars in these priority areas. In the fall of 2001, the INMD performed an environmental scan of researchers, research organizations and policymakers with an interest in our mandate areas. The leading priority among respondents was obesity and healthy body weight. The number of suggestions relevant to this area went well beyond the number of respondents who identified as obesity researchers. As a result of this scan, the INMD's Advisory Board developed a strategic plan with goals to increase our understanding of obesity and healthy body weight through innovative research, surveillance and the identification of policies to prevent obesity and promote healthy living.
Since its inception, CIHR has given multidisciplinary and cross-theme research a high priority. To effectively reverse the trend of increasing prevalence of overweight and obesity, new knowledge both within and across CIHR's four pillars (basic biomedical, clinical, health services and systems, population health and social cultural and environmental influences on health) is required. Even within pillars, innovation and advancement will most likely come from a multidisciplinary perspective. The potential for novel approaches founded in a multidisciplinary perspective is well illustrated by the talks presented in this first session on inflammation and type II diabetes.
Although type II diabetes was characterized as a disease associated with insulin resistance even before insulin could be measured in the blood, the central importance of insulin resistance was not fully recognized until the early 1980s when in vivo methods for the assessment of insulin sensitivity became widely applied. 3 Numerous studies documented the inverse relationship between body mass index and insulin sensitivity suggesting that obesity is a cause of insulin resistance. While increasing body fat was associated with decreasing insulin sensitivity, the muscle mass was thought to be central to insulin resistance given its relative size and significant contribution to glucose utilization. That signaling molecules secreted by adipose tissue played a major role in this insulin resistance was first appreciated in the mid-1990s with the discovery of leptin. That other secretory products of the adipocyte, including the inflammatory cytokine tumour necrosis factor alpha (TNF-a), might control insulin sensitivity was suggested by the work of Hotamisligil, although initially there was considerable resistance to this novel idea. 4 As illustrated by the presentation in this session of Moller, there is now considerable evidence supporting the idea that obesity is, in fact, an inflammatory condition. The adipocyte secretes a number of factors characterized as either pro-or anti-inflammatory, such as TNF-a, aÀ1 acid glycoprotein, serum amyloid A3 and adiponectin. Peroxisome proliferatoractivated receptor gamma (PPARg) is highly expressed in adipose tissue and activation of this receptor with thiazolidienediones decreases production of inflammatory mediators by adipose tissue and enhances insulin sensitivity. Interestingly, PPARg is also expressed in macrophages, but activation of this receptor in that cell type does not seem to affect cytokine secretion although it may have an effect on cell migration and chemokine secretion.
While the relationships between the mass of adipose tissue and cytokine secretion, and between cytokines and insulin resistance, suggested that low levels of adipose tissue would be associated with high insulin sensitivity, the work described by Shulman demonstrates that the relationship is considerably more complex. Shulman describes how fatless mice, created using dominant-negative protein (A-ZIP/F-1) targeted gene expression in the adipocyte, are actually severely insulin resistant and develop diabetes. Upon transplantation of fat tissue into these mice, triglyceride content in muscle and liver returned to normal as did insulin signaling and action, suggesting that development of insulin resistance may be due to alterations in the partitioning of fat between the adipocyte and muscle/liver. Accumulation of triglyceride in the latter tissues leads to impairment of insulin signaling and action. These results are consistent with the effects of PPARg, which also alters the partitioning of fat in adipose tissue, muscle and liver.
Newgard introduced the b cell into the discussion of inflammation and type II diabetes by describing his efforts to identify the signaling pathways most important to protecting the b cell from cytokine-induced cell death. Although these studies were initiated with type I diabetes and the development of death-resistant b cells for transplantation, the results may also be applicable to type II diabetes, especially given the other presentations linking excessive inflammatory mediator secretion to obesity and diabetes.
Failure of the b-cell mass to adequately adapt to the insulin resistance of obesity is associated with the development of type II diabetes. In animal models of type II diabetes, such as the Zucker Diabetic Fatty (ZDF) rat, the lipid-filled islets are more susceptible to cytokine-mediated cytotoxicity. Thus, high circulating levels of proinflammatory cytokines and partitioning of fat into islets may make them more susceptible to death. We have demonstrated that treatment with thiazolindiendiones reduces b-cell death in vivo in ZDF rats 5 and the papers presented in this session suggest reductions in circulating cytokines and partitioning of fat into adipose tissue might be mechanisms for this protective effect. Newgard's efforts to identify the intracellular signaling pathways that confer resistance to cytokine-mediated death in INS-1 cells and those overexpressing the antiapoptotic gene bcl-2 suggest that different and divergent mechanisms may confer protection under different conditions such as cytokine-or lipid-induced cell death. These studies provide a wealth of information that may lead to novel drug targets not only for protection of islet cells for transplantation, but also for enhancing b-cell function and survival in people at high risk for developing type II diabetes.
The work described in this session crosses many disciplinary boundaries. Work directed at autoimmune type I diabetes was shown to have relevance to type II diabetes. What were once considered to be wholly metabolic conditions, obesity and type II diabetes, are now recognized as also being inflammatory diseases, and mediators once thought to be relevant primarily to inflammation are now thought to have important mechanistic roles in the development of insulin resistance and b-cell dysfunction. Although this work primarily arises from a multidisciplinary basic science perspective, it has already had an impact on clinical investigation as illustrated in the presentation by Shoelson in another session in this meeting. Whether these efforts will ultimately help us face the challenge of the growing epidemic of obesity remains to be determined, although a better understanding of the role of fat as both a storage depot and as a regulator of body weight might help us design novel approaches to prevention.
